Heart Disease Clinical Trial
— ACTIVATEOfficial title:
Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?
Verified date | September 2018 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The VA has committed to disseminate a web-based Healthy Living Assessment(HLA) tool and use it as the cornerstone of a personalized prevention plan to engage patients to improve their health behaviors that lead to high health risk. Health risk assessments done in isolation, however, do not generally lead to behavior change. Our study will test the effectiveness of a Shared Decision Making intervention designed to activate Veterans to enroll in effective prevention programs. The intervention will be conducted over the telephone, by a prevention coach, and will be linked to the patients' primary care team. The co-primary outcomes will be patient activation and patient enrollment in prevention programs; 10-year risk of major cardiac events will also be measured.
Status | Completed |
Enrollment | 417 |
Est. completion date | December 30, 2017 |
Est. primary completion date | December 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: To be included in the study, patients must meet the following: - enrolled in primary care at the Durham or Ann Arbor Health Care Systems - have one modifiable risk factor identified by a healthy living assessment (physical inactivity, overweight or obese by BMI, or tobacco user) Exclusion Criteria: Individuals will be excluded if they have any of the following: - have been hospitalized for a stroke, myocardial infarction or coronary artery revascularization in the past three months - have an active diagnosis of psychosis - have any other health condition they feel would impede participation in the study - reside in a nursing home - are severely impaired in hearing or speech, so that they cannot respond to telephone calls - have significant cognitive or memory impairment - do not have access to a telephone - are participating in another prevention intervention study - are already enrolled in a formal prevention service |
Country | Name | City | State |
---|---|---|---|
United States | VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor | Michigan |
United States | Durham VA Medical Center, Durham, NC | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Oddone EZ, Damschroder LJ, Gierisch J, Olsen M, Fagerlin A, Sanders L, Sparks J, Turner M, May C, McCant F, Curry D, White-Clark C, Juntilla K. A Coaching by Telephone Intervention for Veterans and Care Team Engagement (ACTIVATE): A study protocol for a H — View Citation
Oddone EZ, Gierisch JM, Sanders LL, Fagerlin A, Sparks J, McCant F, May C, Olsen MK, Damschroder LJ. A Coaching by Telephone Intervention on Engaging Patients to Address Modifiable Cardiovascular Risk Factors: a Randomized Controlled Trial. J Gen Intern M — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Enrollment in Prevention Services | Proportion of veterans enrolled in effective prevention services including weight loss, healthy eating, physical activity, and smoking cessation programs. | 1 and 6 months (cumulative) | |
Secondary | Patient Activation Measures (PAM) | Patient Activation Measures (PAM) assesses patients capacity to manage their health. Improvement in PAM scores indicate responsiveness to interventions and improvements in self-management behaviors. Minimum score is a zero and maximum is one hundred. Higher score is better. The protocol specifies co-primary outcomes with enrollment in prevention services specified as the most clinically relevant | Baseline assessment | |
Secondary | Patient Activation Measures | Patient Activation Measures (PAM) assesses patients capacity to manage their health. Improvement in PAM scores indicate responsiveness to interventions and improvements in self-management behaviors. Minimum score is a zero and maximum is one hundred. Higher score is better. The protocol specifies co-primary outcomes with enrollment in prevention services specified as the most clinically relevant | 1 month assessment | |
Secondary | Patient Activation Measures | Patient Activation Measures (PAM) assesses patients capacity to manage their health. Improvement in PAM scores indicate responsiveness to interventions and improvements in self-management behaviors. Minimum score is a zero and maximum is one hundred. Higher score is better. The protocol specifies co-primary outcomes with enrollment in prevention services specified as the most clinically relevant | 6 months assessments | |
Secondary | Framingham Risk Score | The Framingham Risk Score is a gender-specific algorithm used to estimate the 10-year cardiovascular risk of an individual. This is not a scale however, lower score indicates less risk. | Baseline | |
Secondary | Framingham Risk Score | The Framingham Risk Score is a gender-specific algorithm used to estimate the 10-year cardiovascular risk of an individual. This is not a scale however, lower score indicates less risk. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03481322 -
Low Sodium Cooking Study
|
N/A | |
Completed |
NCT00001638 -
Magnetic Resonance Imaging of the Blood Vessels of the Heart
|
||
Completed |
NCT02376244 -
The Health Impact of High Intensity Exercise Training With Intervals During Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02523144 -
Dexmedetomidine in Children Having Transthoracic Echocardiography
|
Phase 4 | |
Completed |
NCT02277379 -
Prediction of Bleeding and Transfusion Outcomes and Assessment of Perioperative Platelet Reactivity in Cardiac Surgery
|
N/A | |
Completed |
NCT01871090 -
Remote Device Interrogation In The Emergency Department
|
N/A | |
Completed |
NCT02045641 -
Pleural and Pericardial Effusion Following Open Heart Surgery
|
N/A | |
Active, not recruiting |
NCT01400490 -
Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study
|
N/A | |
Completed |
NCT01192360 -
Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease
|
Phase 3 | |
Terminated |
NCT00935766 -
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
|
Phase 3 | |
Completed |
NCT00745446 -
The Effect of a Retrofit Particle Trap on the Vascular Effects of Diesel Exhaust Inhalation
|
N/A | |
Completed |
NCT00140816 -
Dairy Products and Metabolic Effects (Norwegian Part)
|
N/A | |
Completed |
NCT00178620 -
Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
|
Phase 4 | |
Completed |
NCT00013949 -
Cardiovascular Vulnerability to Particulate Exposure
|
N/A | |
Completed |
NCT01952171 -
The Genetic Basis of Congenital Heart Disease in Africa
|
||
Recruiting |
NCT02933892 -
Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization
|
Phase 4 | |
Completed |
NCT02923518 -
Cardiac Screening of Middle Aged and Older Women and Men (Master Athletes)
|
||
Withdrawn |
NCT02838355 -
Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients
|
N/A | |
Terminated |
NCT02282163 -
Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
|
Phase 3 | |
Active, not recruiting |
NCT02260466 -
Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.
|
N/A |